Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Simple item page
Full item details
- dc.contributor.author
- Yau, Kevin
- Kurtesi, Alexandra
- Qi, Freda
- Delgado-Brand, Melanie
- Tursun, Tulunay R.
- Hu, Queenie
- Dhruve, Miten
- Kandel, Christopher
- Enilama, Omosomi
- Levin, Adeera
- Jiang, Yidi
- Hardy, W. Rod
- Yuen, Darren A.
- Perl, Jeffrey
- Chan, Christopher T.
- Leis, Jerome A.
- Oliver, Matthew J.
- Colwill, Karen
- Gingras, Anne-Claude
- Hladunewich, Michelle A.
- dc.date.accepted
- 2023-09-14
- dc.date.accessioned
- 2024-01-03T15:44:32Z
- dc.date.available
- 2024-01-03T15:44:32Z
- dc.date.issued
- 2023-09-27
- dc.date.submitted
- 2023-04-27
- dc.description.abstract - en
- Neutralization of Omicron subvariants by different bivalent vaccines has not been well evaluated. This study characterizes neutralization against Omicron subvariants in 98 individuals on dialysis or with a kidney transplant receiving the BNT162b2 (BA.4/BA.5) or mRNA-1273 (BA.1) bivalent COVID-19 vaccine. Neutralization against Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 increased by 8-fold one month following bivalent vaccination. In comparison to wild-type (D614G), neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization was not significantly different by bivalent vaccine type for wild-type (D614G) (P = 0.48), BA.1 (P = 0.21), BA.5 (P = 0.07), BQ.1.1 (P = 0.10), nor XBB.1.5 (P = 0.10). Hybrid immunity conferred higher neutralizing antibodies against all Omicron subvariants. This study provides evidence that BNT162b2 (BA.4/BA.5) and mRNA-1273 (BA.1) induce similar neutralization against Omicron subvariants, even when antigenically divergent from the circulating variant.
- dc.identifier.citation
- Yau, K., Kurtesi, A., Qi, F. et al. Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease. Nat Commun 14, 6041 (2023). https://doi.org/10.1038/s41467-023-41678-9
- dc.identifier.doi
- https://doi.org/10.1038/s41467-023-41678-9
- dc.identifier.issn
- 2041-1723
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/1394
- dc.language.iso
- en
- dc.publisher
- Nature Portfolio
- dc.rights - en
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights - fr
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights.openaccesslevel - en
- Gold
- dc.rights.openaccesslevel - fr
- Or
- dc.rights.uri - en
- https://creativecommons.org/licenses/by/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by/4.0/deed.fr
- dc.subject - en
- Health
- dc.subject - fr
- Santé
- dc.subject.en - en
- Health
- dc.subject.fr - fr
- Santé
- dc.title - en
- Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
- dc.type - en
- Article
- dc.type - fr
- Article
- local.acceptedmanuscript.articlenum
- 6041
- local.article.journalissue
- 1
- local.article.journaltitle
- Nature Communications
- local.article.journalvolume
- 14
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: yau-omicron-neutralizing-antibodies-vaccination-kidney-disease-patients.pdf
Size: 970.39 KB
Format: PDF
Collection(s)